©2024 Stanford Medicine
Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer
Not Recruiting
Trial ID: NCT00946673
Purpose
The purpose of this study is to determine the maximum tolerated dose (MTD) of vorinostat
given concurrently with stereotactic radiosurgery (SRS) to treat non-small cell lung cancer
(NSCLCA) brain metastases in patient with 1-4 lesions.
Official Title
A Phase I Trial of Vorinostat Concurrent With Stereotactic Radiotherapy in Treatment of Brain Metastases From Non-Small Cell Lung Cancer
Stanford Investigator(s)
Heather Wakelee
Winston Chen and Phyllis Huang Professor
Scott G. Soltys, MD
Professor of Radiation Oncology (Radiation Therapy) and, by courtesy, of Neurosurgery
Joel Neal, MD, PhD
Associate Professor of Medicine (Oncology)
Steven D. Chang, MD
Robert C. and Jeannette Powell Neurosciences Professor and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Neurology
Iris C. Gibbs, MD, FACR, FASTRO
Professor of Radiation Oncology (Radiation Therapy) and, by courtesy, of Neurosurgery
Eligibility
Inclusion Criteria:
- All patients age 18 years and older with histologically proven non-small cell lung
cancer and 1-4 brain metastases, each measuring less than 2 cm will be eligible. Prior
surgery or radiation is allowed as long as the target metastatic lesion(s) has not
been treated with previous radiation.
- Adequate organ function (section 3.1.10).
- ECOG performance status 0-2.
- Life expectancy of >=12 weeks.
- Systemic chemotherapy washout period >=7 days.
Exclusion Criteria:
Patients who have previously been treated with whole brain irradiation, pediatric patients
(age <18), pregnant women, and patients who are unable to give informed consent.
Intervention(s):
drug: Vorinostat
procedure: Radiation Therapy
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
ccto-office@stanford.edu
650-498-7061